People with polycystic kidney disease do take GLP-1 drugs, for weight or for diabetes, and the one matched study of them found no signal of kidney harm across 320 pairs [1]. Acute kidney injury was no more common on semaglutide, and follow-up eGFR was higher, 57.52 against 50.93 mL/min/1.73 m2. What that study cannot show is that the drug protects the kidneys, and the reviews on the question are clear that a GLP-1 is not a treatment for the disease itself. The decision about taking one sits with a nephrologist, for the same reasons it does in later-stage kidney disease on dialysis.
The study, and who was in it
Autosomal dominant polycystic kidney disease is inherited, progressive, and short on treatment options, and semaglutide has shown kidney benefits in other populations, which is what prompted researchers to look [1]. They searched a large research network for adults with the disease between 2000 and 2024 and excluded anyone on an SGLT2 inhibitor, tolvaptan or another GLP-1. Among 45,613 patients, 323 eligible semaglutide users remained, and 320 of them were matched one to one against non-users.
Excluding tolvaptan matters, because tolvaptan is the drug that treatment of this disease is built around. The study compares semaglutide against no particular treatment rather than against the standard of care, and it says nothing at all about taking the two together.
What moved, and what did not
Follow-up eGFR came out higher on semaglutide, and progression to stage 5 chronic kidney disease was lower, with a hazard ratio of 0.447 and a confidence interval from 0.230 to 0.872. Volume depletion and death from any cause were also less common among the users. End-stage kidney disease, acute kidney injury and urinary tract infection showed no significant difference either way.
The same creatinine problem runs through other kidney results on this site, including the contrast kidney injury cohort, and the muscle side of it is covered in the muscle loss guide. A filtration marker that does not come from muscle, such as cystatin C, is the usual way to separate the two readings, and it is not among the outcomes the study reports.
What the reviews say
Two reviews have looked at whether these drugs could slow the disease. The first points to animal findings and to the metabolic changes the drugs produce, in weight, blood pressure and inflammation, as reasons for interest. It concludes that further clinical studies are needed on both efficacy and safety before the drugs could be used for it [2].
The second goes further into the biology, arguing that obesity and visceral fat may shape how fast cysts grow and kidney function falls, which would make GLP-1 drugs plausible candidates alongside tolvaptan rather than substitutes for it [3]. It describes early-phase trials in progress, lists co-administration with tolvaptan among the open questions, and states plainly that GLP-1 therapy should not currently be regarded as a treatment for the disease.
Where that leaves someone with the disease
For a person with polycystic kidney disease who is being offered a GLP-1 for weight or diabetes, this cohort flagged no kidney harm and the reviews promise no kidney benefit. The heavier kidney claims for this drug come from the FLOW trial in diabetic kidney disease, a different condition. The question still unanswered is whether the drug changes the course of the cysts themselves, and that is what the trials now under way were designed to find out.